Literature DB >> 15199432

Homozygous familial hypercholesterolemia and its management.

Adrian David Marais1, Jean Catherine Firth, Dirk Jacobus Blom.   

Abstract

Mutations in the low-density lipoprotein (LDL) receptor gene cause familial hypercholesterolemia. In homozygous familial hypercholesterolemia, both genes for the LDL- receptor are mutated and LDL levels are markedly elevated. High-density lipoprotein cholesterol concentration is often reduced and lipoprotein(a) levels are high when corrected for apolipoprotein(a) isoforms. Cutaneous and tendinous xanthomata develop in childhood and are the most common reason for initial presentation. The diagnosis can be confirmed by analysis of LDL-receptor genes or studies of LDL receptor function in cultured cells. Severe aortic and coronary atherosclerosis usually occurs within the first or second decades of life. Left ventricular outflow tract obstruction may be at the level of the aortic valve or the supravalvar aorta. Treatment for the hyperlipidemia is with plasmapheresis, high-dose statins, and ezetimibe. Liver transplantation reverses the metabolic defect but requires chronic immunosupression, and rejection may still occur. Liver transplantation is indicated if cardiac transplantation becomes necessary. Portocaval shunt may still play a role in patients with coronary artery disease who do not have access to plasmapheresis. Gene therapy is currently not practicable but is being actively developed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15199432     DOI: 10.1055/s-2004-822985

Source DB:  PubMed          Journal:  Semin Vasc Med        ISSN: 1528-9648


  11 in total

Review 1.  Familial hypercholesterolemia: developments in diagnosis and treatment.

Authors:  Gerald Klose; Ulrich Laufs; Winfried März; Eberhard Windler
Journal:  Dtsch Arztebl Int       Date:  2014-08-04       Impact factor: 5.594

2.  Eruptive Xanthomas as Cutaneous Manifestation of Familial Combined Dyslipidaemia in an Eleven-year-old: A Case Report.

Authors:  Anupa Khadka; Sabina Bhattarai
Journal:  JNMA J Nepal Med Assoc       Date:  2020-03       Impact factor: 0.406

Review 3.  Lomitapide and Mipomersen-Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis.

Authors:  Dirk J Blom; Frederick J Raal; Raul D Santos; A David Marais
Journal:  Curr Atheroscler Rep       Date:  2019-11-19       Impact factor: 5.113

Review 4.  Management of patients with familial hypercholesterolaemia.

Authors:  Željko Reiner
Journal:  Nat Rev Cardiol       Date:  2015-06-16       Impact factor: 32.419

Review 5.  Familial dyslipidaemias: an overview of genetics, pathophysiology and management.

Authors:  Sahar B Hachem; Arshag D Mooradian
Journal:  Drugs       Date:  2006       Impact factor: 9.546

6.  Surgical portosystemic shunts and the Rex bypass in children: a single-centre experience.

Authors:  Sukru Emre; Christina Dugan; Tamara Frankenberg; Lisa Cooper Hudgins; Rosemarie Gagliardi; A Tarik Artis; Gonzalo Rodriguez-Laiz; Gabriel Gondolesi; Benjamin L Shneider; Nanda Kerkar
Journal:  HPB (Oxford)       Date:  2009-05       Impact factor: 3.647

Review 7.  Hyperlipidaemia in paediatric patients: the role of lipid-lowering therapy in clinical practice.

Authors:  Anthony S Wierzbicki; Adie Viljoen
Journal:  Drug Saf       Date:  2010-02-01       Impact factor: 5.606

8.  Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study.

Authors:  Marina Cuchel; Emma A Meagher; Hendrik du Toit Theron; Dirk J Blom; A David Marais; Robert A Hegele; Maurizio R Averna; Cesare R Sirtori; Prediman K Shah; Daniel Gaudet; Claudia Stefanutti; Giovanni B Vigna; Anna M E Du Plessis; Kathleen J Propert; William J Sasiela; LeAnne T Bloedon; Daniel J Rader
Journal:  Lancet       Date:  2012-11-02       Impact factor: 79.321

9.  Clinical course of homozygous familial hypercholesterolemia during childhood: report on 4 unrelated patients with homozygous or compound heterozygous mutations in the LDLR gene.

Authors:  Jolanta Kubalska; Magdalena Chmara; Janusz Limon; Aldona Wierzbicka; Sylwester Prokurat; Janina Szaplyko; Agnieszka Kowalik; Hanna Mierzewska; Joep C Defesche; Ewa Pronicka
Journal:  J Appl Genet       Date:  2008       Impact factor: 3.240

10.  Role of genetic changes in the progression of cardiovascular diseases.

Authors:  S A Sheweita; H Baghdadi; A R Allam
Journal:  Int J Biomed Sci       Date:  2011-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.